CompletedInterventionalPhase 3Last updated Nov 18, 2010

Treatment of Immunoglobulin A (IgA) Nephropathy by Angiotensin-Converting Enzyme (ACE) Inhibitor

Treatment of Early Immunoglobulin A Nephropathy by ACE Inhibitor - a Randomized Controlled Trial

Overview

ClinicalTrials.gov ID: NCT00437463
Lead Sponsor: SanofiINDUSTRY
Brief Summary: To evaluate the efficacy of the ACE inhibitor ramipril in the treatment of early IgA nephropathy.
Study Type: Interventional

Status

Study Record Dates

NCT01225445Completed

Treatment of Early Immunoglobulin A Nephropathy by Angiotensin Converting Enzyme Inhibitor - A Randomized Controlled Trial

NCT03357653Unknown status

Beginning of Effective and Safe Treatment in Immunoglobulin A-1 Nephropathy-1

NCT05824390Unknown status

A Randomized, Controlled Clinical Study of Rituximab in Treatment of Primary IgA Nephropathy

NCT01115426Completed

Inhibitors of Angiotensin II in Proteinuric Mesangioproliferative Glomerulonephritis

NCT00498368Completed

Rituximab in Progressive Immunoglobulin A (IgA) Nephropathy

NCT00378443Unknown status

ACEi/ARB Alone Versus ACEi/ARB Plus Steroids in the Treatment of Primary IgA Nephropathy, a RCT